TOP TEN perturbations for 1553622_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553622_a_at
Selected probe(set): 1553622_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553622_a_at (1553622_a_at) across 6672 perturbations tested by GENEVESTIGATOR:

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (medullary carcinoma, NOS; primary)

Relative Expression (log2-ratio):5.723715
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)

Relative Expression (log2-ratio):5.564472
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (metaplastic carcinoma, NOS; primary)

Relative Expression (log2-ratio):5.551256
Number of Samples:2 / 3
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (metaplastic carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with metaplastic carcinoma (NOS).

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (cribriform carcinoma; primary)

Relative Expression (log2-ratio):5.2007713
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (cribriform carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with cribriform carcinoma.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (inflammatory carcinoma; primary)

Relative Expression (log2-ratio):5.1257267
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (inflammatory carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with inflammatory carcinoma.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (lobular carcinoma, NOS; primary)

Relative Expression (log2-ratio):4.5667496
Number of Samples:2 / 39
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (lobular carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with lobular carcinoma (NOS).

breast cancer study 50 (subtype V) / breast cancer study 50 (subtype I)

Relative Expression (log2-ratio):4.2681794
Number of Samples:41 / 37
Experimental breast cancer study 50 (subtype V)
Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype V. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype V:predominantly positive for ER, predominantly positive for PR, predominantly negative for HER2, long-term survival with hormonal therapy alone following surgery and/or radiation therapy, adjuvant chemotherapy did not provide any survival benefit in early stages, consistent with a unique subset of luminal A intrinsic type, smaller tumors dominate (T-stage), least likely to metastasize, increased expressions of cell cycle/proliferation genes, low risk of distant recurrence
Control breast cancer study 50 (subtype I)
Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype I. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype I:predominantly negative for ER, variable for PR expression, predominantly negative for HER2, in concordance with chemosensitive basal-like intrinsic type, CMF yielded survival outcome similar to those of CAF, increased expressions of cell cycle/proliferation genes, high risk of distant recurrence

breast cancer study 16 (mix. inv. dc lc) / adjacent breast tissue

Relative Expression (log2-ratio):4.1845284
Number of Samples:4 / 27
Experimental breast cancer study 16 (mix. inv. dc lc)
Primary mixed invasive ductal and lobular carcinoma tissue sample derived from the breasts of female patients after surgery.
Control adjacent breast tissue
Histologically normal breast tissue samples obtained from a clinically unaffected site from patients with primary invasive breast cancer.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (infiltrating duct carcinoma, NOS; primary)

Relative Expression (log2-ratio):4.0192795
Number of Samples:2 / 277
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (infiltrating duct carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with infiltrating duct carcinoma (NOS).

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (ductal and lobular carcinoma; primary)

Relative Expression (log2-ratio):3.8759766
Number of Samples:2 / 4
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (ductal and lobular carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with ductal and lobular carcinoma.